---
document_datetime: 2025-12-29 09:02:08
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/adakveo.html
document_name: adakveo.html
version: success
processing_time: 0.1233814
conversion_datetime: 2025-12-29 22:02:07.910744
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Adakveo

[RSS](/en/individual-human-medicine.xml/67350)

##### Revoked

This medicine's authorisation has been revoked

crizanlizumab Medicine Human Revoked

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Adakveo](#news-on)
- [More information on Adakveo](#more-information-on-adakveo-32624)
- [More information on Adakveo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Adakveo has been revoked by the European Commission.

Adakveo : EPAR - Medicine overview

Reference Number: EMA/446082/2020

English (EN) (208.21 KB - PDF)

**First published:** 24/11/2020

**Last updated:** 21/08/2023

[View](/en/documents/overview/adakveo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-450)

български (BG) (258.53 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/bg/documents/overview/adakveo-epar-medicine-overview_bg.pdf)

español (ES) (196.57 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/es/documents/overview/adakveo-epar-medicine-overview_es.pdf)

čeština (CS) (232.71 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/cs/documents/overview/adakveo-epar-medicine-overview_cs.pdf)

dansk (DA) (192.47 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/da/documents/overview/adakveo-epar-medicine-overview_da.pdf)

Deutsch (DE) (201.08 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/de/documents/overview/adakveo-epar-medicine-overview_de.pdf)

eesti keel (ET) (172.19 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/et/documents/overview/adakveo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (256.85 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/el/documents/overview/adakveo-epar-medicine-overview_el.pdf)

français (FR) (197.58 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/fr/documents/overview/adakveo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (222.55 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/hr/documents/overview/adakveo-epar-medicine-overview_hr.pdf)

italiano (IT) (193.4 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/it/documents/overview/adakveo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (236.29 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/lv/documents/overview/adakveo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (231.44 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/lt/documents/overview/adakveo-epar-medicine-overview_lt.pdf)

magyar (HU) (226.21 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/hu/documents/overview/adakveo-epar-medicine-overview_hu.pdf)

Malti (MT) (238.09 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/mt/documents/overview/adakveo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (195.9 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/nl/documents/overview/adakveo-epar-medicine-overview_nl.pdf)

polski (PL) (233.87 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/pl/documents/overview/adakveo-epar-medicine-overview_pl.pdf)

português (PT) (198.01 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/pt/documents/overview/adakveo-epar-medicine-overview_pt.pdf)

română (RO) (232.25 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/ro/documents/overview/adakveo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (227.5 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sk/documents/overview/adakveo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (228.97 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sl/documents/overview/adakveo-epar-medicine-overview_sl.pdf)

Suomi (FI) (187.61 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/fi/documents/overview/adakveo-epar-medicine-overview_fi.pdf)

svenska (SV) (192.38 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sv/documents/overview/adakveo-epar-medicine-overview_sv.pdf)

Adakveo : EPAR - Risk-management-plan summary

English (EN) (340.06 KB - PDF)

**First published:** 24/11/2020

**Last updated:** 21/08/2023

[View](/en/documents/rmp-summary/adakveo-epar-risk-management-plan-summary_en.pdf)

## Product information

Adakveo : EPAR - Product information

English (EN) (1.36 MB - PDF)

**First published:** 24/11/2020

**Last updated:** 21/08/2023

[View](/en/documents/product-information/adakveo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-913)

български (BG) (1.59 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/bg/documents/product-information/adakveo-epar-product-information_bg.pdf)

español (ES) (1.48 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/es/documents/product-information/adakveo-epar-product-information_es.pdf)

čeština (CS) (1.85 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/cs/documents/product-information/adakveo-epar-product-information_cs.pdf)

dansk (DA) (1.35 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/da/documents/product-information/adakveo-epar-product-information_da.pdf)

Deutsch (DE) (1.4 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/de/documents/product-information/adakveo-epar-product-information_de.pdf)

eesti keel (ET) (1.3 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/et/documents/product-information/adakveo-epar-product-information_et.pdf)

ελληνικά (EL) (4.58 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/el/documents/product-information/adakveo-epar-product-information_el.pdf)

français (FR) (1.47 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/fr/documents/product-information/adakveo-epar-product-information_fr.pdf)

hrvatski (HR) (1.82 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/hr/documents/product-information/adakveo-epar-product-information_hr.pdf)

íslenska (IS) (1.58 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/is/documents/product-information/adakveo-epar-product-information_is.pdf)

italiano (IT) (1.92 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/it/documents/product-information/adakveo-epar-product-information_it.pdf)

latviešu valoda (LV) (1.36 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/lv/documents/product-information/adakveo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.46 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/lt/documents/product-information/adakveo-epar-product-information_lt.pdf)

magyar (HU) (1.47 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/hu/documents/product-information/adakveo-epar-product-information_hu.pdf)

Malti (MT) (1.77 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/mt/documents/product-information/adakveo-epar-product-information_mt.pdf)

Nederlands (NL) (1.3 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/nl/documents/product-information/adakveo-epar-product-information_nl.pdf)

norsk (NO) (1.49 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/no/documents/product-information/adakveo-epar-product-information_no.pdf)

polski (PL) (1.66 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/pl/documents/product-information/adakveo-epar-product-information_pl.pdf)

português (PT) (1.57 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/pt/documents/product-information/adakveo-epar-product-information_pt.pdf)

română (RO) (1.81 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/ro/documents/product-information/adakveo-epar-product-information_ro.pdf)

slovenčina (SK) (1.67 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sk/documents/product-information/adakveo-epar-product-information_sk.pdf)

slovenščina (SL) (1.58 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sl/documents/product-information/adakveo-epar-product-information_sl.pdf)

Suomi (FI) (1.3 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/fi/documents/product-information/adakveo-epar-product-information_fi.pdf)

svenska (SV) (1.42 MB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sv/documents/product-information/adakveo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** 004874/A20/0013 03/08/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Adakveo : EPAR - All authorised presentations

English (EN) (115.27 KB - PDF)

**First published:** 24/11/2020

**Last updated:** 21/08/2023

[View](/en/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-111)

български (BG) (130.35 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/bg/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_bg.pdf)

español (ES) (118.8 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/es/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (122.23 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/cs/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (119.44 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/da/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (120.75 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/de/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (114.35 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/et/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (126.63 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/el/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_el.pdf)

français (FR) (118.57 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/fr/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (120.92 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/hr/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (116.95 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/is/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (120.25 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/it/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (122.37 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/lv/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (120.31 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/lt/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (120.09 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/hu/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (124.49 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/mt/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (117.21 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/nl/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (121.81 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/no/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_no.pdf)

polski (PL) (122.47 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/pl/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_pl.pdf)

português (PT) (119.5 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/pt/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_pt.pdf)

română (RO) (121.18 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/ro/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (122.07 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sk/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (117.66 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sl/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (115.45 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/fi/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (116.27 KB - PDF)

**First published:**

24/11/2020

**Last updated:**

21/08/2023

[View](/sv/documents/all-authorised-presentations/adakveo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Adakveo Active substance Crizanlizumab International non-proprietary name (INN) or common name crizanlizumab Therapeutic area (MeSH) Anemia, Sickle Cell Anatomical therapeutic chemical (ATC) code B06AX01

### Pharmacotherapeutic group

Other hematological agents

### Therapeutic indication

Adakveo is indicated for the prevention of recurrent vaso occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older.

It can be given as an add on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.

## Authorisation details

EMA product number EMEA/H/C/004874

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 23/07/2020 Marketing authorisation issued 28/10/2020 Revocation of marketing authorisation 03/08/2023 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Adakveo Article-20 procedure - Annex - Scientific conclusions

English (EN) (182.79 KB - PDF)

**First published:** 09/08/2023

**Last updated:** 21/08/2023

[View](/en/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_en.pdf)

[Other languages (22)](#file-language-dropdown-76)

български (BG) (230.15 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/bg/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_bg.pdf)

español (ES) (181.21 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/es/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_es.pdf)

čeština (CS) (227.16 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/cs/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_cs.pdf)

dansk (DA) (188.81 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/da/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_da.pdf)

Deutsch (DE) (220.44 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/de/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_de.pdf)

eesti keel (ET) (162.9 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/et/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_et.pdf)

ελληνικά (EL) (244.66 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/el/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_el.pdf)

français (FR) (207.95 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/fr/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_fr.pdf)

hrvatski (HR) (208.58 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/hr/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_hr.pdf)

italiano (IT) (200.27 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/it/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_it.pdf)

latviešu valoda (LV) (225.08 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/lv/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (200.49 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/lt/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_lt.pdf)

magyar (HU) (202.69 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/hu/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_hu.pdf)

Malti (MT) (297.5 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/mt/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_mt.pdf)

Nederlands (NL) (200.26 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/nl/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_nl.pdf)

polski (PL) (214.25 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/pl/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_pl.pdf)

português (PT) (193.71 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/pt/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_pt.pdf)

română (RO) (204.32 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/ro/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_ro.pdf)

slovenčina (SK) (211.08 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/sk/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_sk.pdf)

slovenščina (SL) (201.8 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/sl/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_sl.pdf)

Suomi (FI) (176.13 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/fi/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_fi.pdf)

svenska (SV) (187.77 KB - PDF)

**First published:**

09/08/2023

**Last updated:**

21/08/2023

[View](/sv/documents/referral/adakveo-article-20-procedure-annex-scientific-conclusions_sv.pdf)

Adakveo Article-20 procedure - Assessment report

Reference Number: EMA/267688/2023

English (EN) (2.57 MB - PDF)

**First published:** 09/08/2023

**Last updated:** 21/08/2023

[View](/en/documents/referral/adakveo-article-20-procedure-assessment-report_en.pdf)

Adakveo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (238.21 KB - PDF)

**First published:** 05/07/2021

**Last updated:** 21/08/2023

[View](/en/documents/procedural-steps-after/adakveo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Adakveo-H-C-PSUSA-00010888-202011 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/378769/2021

English (EN) (178.29 KB - PDF)

**First published:** 30/08/2021

**Last updated:** 21/08/2023

[View](/en/documents/scientific-conclusion/adakveo-h-c-psusa-00010888-202011-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Adakveo : EPAR - Public assessment report

Adopted

Reference Number: EMA/427120/2020

English (EN) (7.2 MB - PDF)

**First published:** 24/11/2020

**Last updated:** 21/08/2023

[View](/en/documents/assessment-report/adakveo-epar-public-assessment-report_en.pdf)

Adakveo: Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-516929

English (EN) (619.53 KB - PDF)

**First published:** 11/08/2020

**Last updated:** 21/08/2023

[View](/en/documents/orphan-maintenance-report/adakveo-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Adakveo

Adopted

Reference Number: EMA/373250/2020

English (EN) (206.65 KB - PDF)

**First published:** 24/07/2020

**Last updated:** 21/08/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-adakveo_en.pdf)

#### News on Adakveo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-may-2023) 26/05/2023

[Revocation of authorisation for sickle cell disease medicine Adakveo](/en/news/revocation-authorisation-sickle-cell-disease-medicine-adakveo) 26/05/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023) 27/01/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

#### More information on Adakveo

This product was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-12-1034) on 9 August 2012. Adakveo was withdrawn from the Community register by the European Commission in August 2023 at the time of the withdrawal of the marketing authorisation.

#### More information on Adakveo

- [Adakveo - referral](/en/medicines/human/referrals/adakveo)
- [Adakveo - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/adakveo)
- [Adakveo - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/adakveo-0)
- [Adakveo (crizanlizumab) PRegnancy outcomes Intensive Monitoring (PRIM) (Adakveo (crizanlizumab) PRIM) - post-authorisation study](https://catalogues.ema.europa.eu/study/47770)

**This page was last updated on** 29/09/2023

## Share this page

[Back to top](#main-content)